Recombinant protein polymer-antibody conjugates for applications in nanotechnology and biomedicine
Copyright © 2022 Elsevier B.V. All rights reserved..
Currently, there are over 100 antibody-based therapeutics on the market for the treatment of various diseases. The increasing importance of antibody treatment is further highlighted by the recent FDA emergency use authorization of certain antibody therapies for COVID-19 treatment. Protein-based materials have gained momentum for antibody delivery due to their biocompatibility, tunable chemistry, monodispersity, and straightforward synthesis and purification. In this review, we discuss progress in engineering the molecular features of protein-based biomaterials, in particular recombinant protein polymers, for introducing novel functionalities and enhancing the delivery properties of antibodies and related binding protein domains.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:191 |
|---|---|
| Enthalten in: |
Advanced drug delivery reviews - 191(2022) vom: 01. Dez., Seite 114570 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goncalves, Antonio G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 01.12.2022 Date Revised 23.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.addr.2022.114570 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347439675 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347439675 | ||
| 003 | DE-627 | ||
| 005 | 20231226033829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.addr.2022.114570 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347439675 | ||
| 035 | |a (NLM)36228897 | ||
| 035 | |a (PII)S0169-409X(22)00460-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goncalves, Antonio G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recombinant protein polymer-antibody conjugates for applications in nanotechnology and biomedicine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2022 | ||
| 500 | |a Date Revised 23.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a Currently, there are over 100 antibody-based therapeutics on the market for the treatment of various diseases. The increasing importance of antibody treatment is further highlighted by the recent FDA emergency use authorization of certain antibody therapies for COVID-19 treatment. Protein-based materials have gained momentum for antibody delivery due to their biocompatibility, tunable chemistry, monodispersity, and straightforward synthesis and purification. In this review, we discuss progress in engineering the molecular features of protein-based biomaterials, in particular recombinant protein polymers, for introducing novel functionalities and enhancing the delivery properties of antibodies and related binding protein domains | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a Polymers |2 NLM | |
| 650 | 7 | |a Biocompatible Materials |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 700 | 1 | |a Hartzell, Emily J |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, Millicent O |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wilfred |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced drug delivery reviews |d 1995 |g 191(2022) vom: 01. Dez., Seite 114570 |w (DE-627)NLM086826522 |x 1872-8294 |7 nnns |
| 773 | 1 | 8 | |g volume:191 |g year:2022 |g day:01 |g month:12 |g pages:114570 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.addr.2022.114570 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 191 |j 2022 |b 01 |c 12 |h 114570 | ||